戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  sequestration and desensitization of the V2 vasopressin receptor.
2 lial cells expressing the Galphas-coupled V2 vasopressin receptor.
3 en-transmembrane receptor, the Gs-coupled V2 vasopressin receptor.
4 s in the neural distribution of oxytocin and vasopressin receptors.
5  modulatory functions of ILG on dopamine and vasopressin receptors.
6 zation of the parathyroid hormone and type 2 vasopressin receptors.
7  properties on the insect and human oxytocin/vasopressin receptors.
8 n receptor is only 30 to 50% homologous with vasopressin receptors.
9 llent selectivity against the human arginine vasopressin receptors.
10 nt series of soluble receptor analogs, named vasopressin receptor 1 elements on a soluble scaffold (V
11 nsitization was investigated by studying two vasopressin receptors 14 and 27 amino acids shorter than
12                       Expression of arginine vasopressin receptor 1a (Avpr1a) and oxytocin receptor (
13                  Here, we show that Arginine vasopressin receptor 1a (AVPR1A) in the central nucleus
14                     A new class of selective vasopressin receptor 1A (V(1A)) antagonists was identifi
15 ingle 20 mg intravenous dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, on exp
16 ats RS1, RS3 and AVR in the AVPR1A (arginine vasopressin receptor 1a) gene and STin2 in the SLC6A4 (s
17 adrenomedullin, adrenomedullin receptor, and vasopressin receptor 1a.
18 le-nucleotide polymorphism near the arginine vasopressin receptor 1b gene is associated with serious
19 e-nucleotide polymorphism (near the arginine vasopressin receptor 1b gene) was significantly associat
20 n of STAT3 in renal cystic cells depended on vasopressin receptor 2 (V2R) signaling, which increased
21 ncentration mechanism by modulating arginine vasopressin receptor 2 and AQP2 expression in the inner
22 art, to decreased expression of the arginine vasopressin receptor 2 in ptip mutants.
23 mutase 1, lysozyme, serum amyloid A, prions, vasopressin receptor 2, and alpha-1-antitrypsin.
24 r different phosphopeptides derived from the vasopressin receptor-2 (V2R) C-tail.
25                                   First, the vasopressin receptor-2 agonist, dDAVP, was delivered to
26 ture-function relationship studies of the V2 vasopressin receptor, a prototypical G(s)-coupled recept
27  mutations in rhodopsin, cone opsins, the V2 vasopressin receptor, ACTH receptor, and calcium-sensing
28 icate that in cultured cortical neurons, V1a vasopressin receptor activation leads to induction of th
29 ent was activated by phospholipase C-coupled vasopressin receptor activation or by the diacylglycerol
30 from our laboratory has demonstrated that V1 vasopressin receptor agonist (V1 agonist) induces a comp
31  treatment of mpkCCD14 cells with the type 2 vasopressin receptor agonist dDAVP increased mRNA and pr
32 sure of cortical neurons to the selective V1 vasopressin receptor agonist, [Phe2,Orn8]-vasotocin, (V1
33 and-induced endocytosis of two GPCRs: the V2 vasopressin receptor and beta-2 adrenergic receptor, wit
34  from receptor to receptor (400% with type 2 vasopressin receptor and only 30% with M2R), expression
35 ing increased male expression of angiotensin-vasopressin receptor and prolactin receptor, decreased 5
36 ic release of vasopressin and the cloning of vasopressin receptors and of vasopressin-regulated water
37 ectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 (
38 erenol (luteinizing hormone receptor, type 2 vasopressin receptor, and types 1 and 2 beta-adrenergic
39     In patients with advanced heart failure, vasopressin receptor antagonism with conivaptan resulted
40 erapy, infusion of hypertonic saline, use of vasopressin receptor antagonist (vaptans), or use of ren
41                         The first nonpeptide vasopressin receptor antagonist (VRA) is now approved by
42 receptor antagonist), but not by an oxytocin/vasopressin receptor antagonist or a micro-opioid recept
43                                Satavaptan (a vasopressin receptor antagonist) was investigated for tr
44 on of [3H]IP1 was blocked by a selective V1a vasopressin receptor antagonist, (Phenylac1, D-Tyr(Me)2,
45 treatment with conivaptan, a dual V(1a)/V(2) vasopressin receptor antagonist, at a single intravenous
46 ct of oral administration of a nonpeptide V2 vasopressin receptor antagonist, OPC 31260, was therefor
47                             The effect of V2 vasopressin receptor antagonist, OPC-31260, was then inv
48                                              Vasopressin receptor antagonists, urea, and loop diureti
49                                              Vasopressin receptors appear to have a regulatory role i
50 n are identical, but the human V(1)- or V(2)-vasopressin receptors are approximately 80% homologous w
51                      Using the GS-coupled V2 vasopressin receptor as a model system, we systematicall
52     Examination of the structure of [Arg(8)]-vasopressin receptors (AVPRs) and oxytocin receptors (OT
53                                 The human V2 vasopressin receptor belongs to the superfamily of G pro
54 animals, while antagonists of the opioid and vasopressin receptors blocked hindlimb postural asymmetr
55 ermitted an alpha s-coupled receptor (the V2 vasopressin receptor but not the beta 2-adrenergic recep
56      Moreover, the m3 muscarinic and the V1a vasopressin receptors but not the GRP receptor also gain
57  alpha q-coupled receptors (bombesin and V1a vasopressin receptors but not the oxytocin receptor) to
58 observed with other receptors such as the V2 vasopressin receptor, but did couple with the clathrin a
59 a fetus is not mediated by stimulation of V1-vasopressin receptors, but is dependent on alpha-adrener
60 t that occupation of a small fraction of V1a vasopressin receptors by AVP results in stimulation of p
61 ion) by vasopressin-induced activation of V2 vasopressin receptors co-expressed at similar levels.
62 ein, the oxytocin receptor, and the arginine vasopressin receptor contain VDREs for activation.
63               The C terminus of the human V2 vasopressin receptor contains multiple phosphorylation s
64    The extracellular portion of the human V2 vasopressin receptor contains one site susceptible to N-
65 e two classes of receptors (beta(2)AR and V2 vasopressin receptors), demonstrate reversal of the patt
66    Among monogamous prairie voles, levels of vasopressin receptor (encoded by the gene avpr1a) in bra
67                                       The V2 vasopressin receptor expressed transiently was glycosyla
68 d species-specific patterns of oxytocin- and vasopressin-receptor expression in the brain that appear
69 may contribute to the species differences in vasopressin-receptor expression.
70                          Activation of V(1a) vasopressin receptors facilitates neuronal excitability
71 ule agonists and antagonists of the oxytocin/vasopressin receptor family and identified two, SR49059
72                                          The vasopressin receptor family is unique among all classes
73 ved for site amino acid replacement rates in vasopressin receptor family proteins (VPRs).
74                                      The V1a vasopressin receptor, for example, is preferentially lin
75 t changes in the regulation of oxytocin- and vasopressin-receptor gene expression underlie these spec
76 expression variations of the oxytocin and/or vasopressin receptor genes OXTR and AVPR1A, respectively
77 r these conditions, the expression of OT and vasopressin receptor genes, as well as marker genes of s
78                Three Drosophila GPCRs in the vasopressin receptor group respond to crustacean cardioa
79  has a high degree of selectivity toward the vasopressin receptors, >10,000 for hV1a/hV1b and approxi
80 ompulsive disorder, and polymorphisms of V1a vasopressin receptor have been linked to autism.
81 >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no si
82 racellular elements of the human V1-vascular vasopressin receptor (hV1R).
83 The antagonist bound specifically to the V1a vasopressin receptor in crude rat liver membranes with a
84 ansduction mechanism associated with the V1a vasopressin receptor in enriched cultures of cortical ne
85 e value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent p
86 demonstrate an effector mechanism for the V1 vasopressin receptor in the cerebral cortex and provide
87 s aggression by increasing the number of V1a vasopressin receptors in the AH.
88 s aggression by increasing the number of V1a vasopressin receptors in the anterior hypothalamus (AH).
89  selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not assoc
90 phatidylinositol hydrolysis), whereas the V2 vasopressin receptor is selectively coupled to Gs (bioch
91 of this approach, a series of nine mutant V2 vasopressin receptors known to be responsible for X-link
92 93 cells, stimulation of the beta(2)AR or V2 vasopressin receptor leads, respectively, to transient o
93                                              Vasopressin receptor levels, however, were dramatically
94 s that is initiated by G-protein-coupled V1a vasopressin receptor-mediated cytoplasmic and nuclear Ca
95 n important role for development of oxytocin/vasopressin receptor modulators that would enable clear
96 ace levels of two folding-defective human V2-vasopressin receptor mutants, which were susceptible to
97 hat the naturally occurring loss of function vasopressin receptor mutation R137H, which is associated
98  contractile responses suggests increases in vasopressin receptor number, affinity, and/or efficiency
99  nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM,
100 thway for an orphan GPCR referred to here as vasopressin receptor-related receptor 1 (VRR1) by genera
101 flammatory genes and disappearance of the V2 vasopressin receptor, resulting in loss of AQP2 (confirm
102  has made possible the selective blockade of vasopressin receptor subtypes for therapeutic purposes.
103 luence the HPA axis, such as the vasopressin-vasopressin receptor system.
104 thetic phosphopeptide mimicking the human V2 vasopressin receptor tail that binds and functionally ac
105                    The presence of all known vasopressin receptors that are, together, potentially ca
106 eptors including CXCR4, mu-Opioid and type-2 Vasopressin receptors that selectively control the activ
107 opressin-regulated water channel) and the V2 vasopressin receptor, that are important to regulated wa
108                 In contrast to the wild-type vasopressin receptor, the nonsignaling R137H receptor is
109           In the present study, we show that vasopressin receptor type-2 (V2R) is localized to cilia
110                                       The V2 vasopressin receptor undergoes ligand-induced sequestrat
111 tide derived from the C terminus of the V(2) vasopressin receptor (V(2)Rpp) or the corresponding unph
112        Reciprocally, Gs enhances IP1 through vasopressin receptor (V1A-R) but not alpha1 adrenergic r
113 ropeptide vasopressin and are prevented by a vasopressin receptor [V1a receptor (V1aR)] antagonist in
114 determine the downstream consequences of V1a vasopressin receptor (V1aR) activation of Ca2+ signaling
115 VPA exposure downregulated prefrontal cortex vasopressin receptor (V1aR) and methyl CpG-binding prote
116 ure and functional expression of a human V1a vasopressin receptor (V1aR) cDNA isolated from human liv
117                             The V1a arginine vasopressin receptor (V1aR) expressed in HEK 293 cells w
118                                      The V1a vasopressin receptor (V1aR) is a member of a family of r
119 nvestigate whether individual differences in vasopressin receptor (V1aR) or oxytocin receptor (OTR) r
120  recently, we have detected mRNA for the V1a vasopressin receptors (V1aRs) in cultured cortical neuro
121                     Palmitoylation of the V2 vasopressin receptor (V2R) and its functional role were
122 nction mutations in the gene encoding the V2 vasopressin receptor (V2R) cause nephrogenic syndrome of
123 tissues through the inhibition of the type-2 vasopressin receptor (V2R) constitutes a validated strat
124                          The internalized V2 vasopressin receptor (V2R) expressed in HEK 293 cells is
125 e caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss
126                        Stimulation of the V2 vasopressin receptor (V2R) in cultured cells or in vivo
127                   Here we demonstrate that a vasopressin receptor (V2R) mutant with truncated third i
128                                       The V2 vasopressin receptor (V2R) plays a key role in the maint
129 entify molecules that might contribute to V2 vasopressin receptor (V2R) trafficking or signaling, we
130 les in the regulation and function of the V2 vasopressin receptor (V2R), a G protein-coupled receptor
131 hey had gain-of-function mutations in the V2 vasopressin receptor (V2R).
132 y-terminal peptide derived from the human V2 vasopressin receptor (V2Rpp).
133  itineraries of wild type (WT) and mutant V2 vasopressin receptors (V2Rs) in polarized Madin-Darby ca
134 y (both of which are related to dopamine and vasopressin receptors), we investigated the binding affi
135                  At least four of these five vasopressin receptors were produced by cell lines exempl
136               For class B receptors (e.g. V2 vasopressin receptors), which recycle slowly, beta-arres
137 nant for nephrogenic diabetes insipidus, the vasopressin receptor with a substitution at the DRY moti

 
Page Top